Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?

Journal of Alzheimer's Disease

Volumn 47, Issue 4, 2015, Pages 1069-1078

  Travassos, Maria ^a   Santana, Isabel ^b   Baldeiras, Inês ^c   Tsolaki, Magda ^d   Gkatzima, Olymbia ^d   Genc, Sermin ^e   Yener, Görsev G ^e   Simonsen, Anja ^f   Hasselbalch, Steen G ^f   Kapaki, Elisabeth ^g   Bourbouli, Mara ^g   Cunha, Rodrigo A ^c   Agostinho, Paula ^c   Blennow, Kaj ^h   Zetterberg, Henrik ^h   Mendes, Vera M ^c   Manadas, Bruno ^c   De Mendonça, Alexandre ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c UNIVERSITY OF COIMBRA   (Portugal)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e DOKUZ EYLUL UNIVERSITY   (Turkey)

^f Mental Health Center Glostrup   (Denmark)

^g UNIVERSITY OF ATHENS   (Greece)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Amyloid ; Biomarkers; Caffeine; Cerebrospinal fluid; Metabolism; Mild cognitive impairment; Phosphotau; Theobromine; Total tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[X-38]; AMYLOID BETA PROTEIN[X-40]; AMYLOID BETA PROTEIN[X-42]; CAFFEINE; PARAXANTHINE; TAU PROTEIN; THEOBROMINE; THEOPHYLLINE; UNCLASSIFIED DRUG; XANTHINE; XANTHINE DERIVATIVE; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CACAO; CEREBROSPINAL FLUID ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; QUESTIONNAIRE; TANDEM MASS SPECTROMETRY; VERY ELDERLY; BLOOD; CEREBROSPINAL FLUID; DIET; MIDDLE AGED;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; CAFFEINE; DIET; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; TAU PROTEINS; THEOBROMINE;

EID: 84939450783     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150374     Document Type: Article

References (39)

1. Fredholm BB, Bättig K, Holmén J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83-133.
2. de Mendonca A, Cunha RA (2010) Putative neuroprotective effects of caffeine in clinical trials. Concluding remarks. J Alzheimers Dis 20(Suppl 1), S249-S252.
3. Dall'Igna OP, Porcíuncula LO, Souza DO, Cunha RA, Lara DR (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138, 1207-1209.
4. Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosineA2a receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol 203, 241-245.
5. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J (2006) Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience 142, 941-952.
6. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, ArendashGW, Holtzman DM, Potter H (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 17, 681-697.
7. Laurent C, Eddarkaoui S, Derisbourg M, Leboucher A, Demeyer D, Carrier S, Schneider M, Hamdane M, Müller CE, Buée L, Blum D (2014) Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. Neurobiol Aging 35, 2079-2090.
8. Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N (2010) Caffeine intake and dementia: Systematic review and metaanalysis. J Alzheimers Dis 20(Suppl 1), S187-204.
9. Cao C, Loewenstein DA, Lin X, Zhang C,Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, Arendash GW (2012) High blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis 30, 559-572.
10. Arendash GW, Cao C (2010) Caffeine and coffee as therapeutics against Alzheimer's disease. J Alzheimers Dis 20 (Suppl 1), S117-S126.
11. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
12. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
13. Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O (2014) Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid -amyloid 42:Across-validation study against amyloid positron emission tomography. JAMA Neurol 71, 1282-1289.
14. Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 11, 58-69.
15. Bocchetta M, Galluzzi S, Kehoe PG, Aguera E, Bernabei R, Bullock R, Ceccaldi M, Dartigues JF, de Mendonca A, Didic M, Eriksdotter M, Félician O, Frölich L, Gertz HJ, Hallikainen M, Hasselbalch SG, Hausner L, Heuser I, Jessen F, Jones RW, Kurz A, Lawlor B, Lleo A, Martinez-Lage P, Mecocci P, Mehrabian S, Monsch A, Nobili F, Nordberg A, Olde Rikkert M, Orgogozo JM, Pasquier F, Peters O, Salmon E, ͆anchez-Castellano C, Santana I, Sarazin M, Traykov L, Tsolaki M, Visser PJ,Wallin AK,Wilcock G,Wilkinson D,Wolf H,Yener G, Zekry D, Frisoni GB (2015) The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimers Dement 11, 195-206. e1.
16. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, Teunissen CE, Parnetti L (2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 10, 808-817.
17. Portet F, Ousset PJ, Visser PJ, Frisoni GB, Nobili F, Scheltens P, Vellas B, Touchon J; MCIWorking Group of the European Consortium on Alzheimer's Disease (EADC)(2006) Mild cognitive impairment (MCI) in medical practice: A critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry 77, 714-718.
18. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edition). American Psychiatric Association, Washington, DC.
19. Willett WC (1998) Food frequency methods. In Nutritional Epidemiology. Oxford University Press, pp. 74-100.
20. Lopes C (2000) Reprodutibilidade e validacão de um questiońario de freqü?encia alimentar [PhD Thesis], Universidade do Porto, Porto.
21. Lopes C, Aro A, Azevedo A, Ramos E, Barros H (2007) Intake and adipose tissue composition of fatty acids and risk of myocardial infarction in a male Portuguese community sample. J Am Diet Assoc 107, 276-286.
22. Somogyi LP (2012) Caffeine intake by the US population. Report. The Food and Drug Administration and Oakridge National Laboratory.
23. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, ͆aez-Valero J, Saka E, Urbani A, Vanmechelen E, Verbeek M, Visser PJ, Teunissen C (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: An update. Biomark Med 6, 419-430.
24. Andreasen N, Hesse C, Davidsson P, Wallin A, Minthon L, Winblad B, Vanderstichele H, Vanmechelen E, Blennow K (1999) Cerebrospinal fluid -amyloid(1-42) in Alzheimer's disease: Differences between early-and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680.
25. Blennow K, Wallin A, A gren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid: A biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 26, 231-245.
26. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van der Perre B, Sjögren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
27. Maia L, de Mendonca A (2002) Does caffeine intake protect from Alzheimer's disease? Eur J Neurol 9, 377-382.
28. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, Andreasen N, Zetterberg H, Andreasson U, Blennow K (2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010, pii: 986310.
29. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Walter BK, Tsai E, Plymate SR, Postupna N,Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S (2011) Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. Arch Neurol 68, 743-752.
30. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L (2014) Mild cognitive impairment: A concept in evolution. J Intern Med 275, 214-228.
31. Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, ShawLM, Trojanowski JQ, ZetterbergH, BlennowK,Weiner MW; Alzheimer's Disease Neuroimaging Initiative (2015) Independent information from cerebrospinal fluid amyloid- and florbetapir imaging in Alzheimer's disease. Brain 138, 772-783.
32. Bonati M, Latini R, Galletti F, Young JF, Tognoni G, Garattini S (1982) Caffeine disposition after oral doses. Clin Pharmacol Ther 32, 98-106.
33. Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB (2012) PharmGKB summary: Caffeine pathway. Pharmacogenet Genomics 22, 389-395.
34. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, Hosea N, Liu J, Nelson FR, Szewc MA, Van Deusen J (2006) Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration. Drug Metab Dispos 34, 1443-1447.
35. Judelson DA, Preston AG, Miller DL, Muñoz CX, Kellogg MD, Lieberman HR (2013) Effects of theobromine and caffeine on mood and vigilance. J Clin Psychopharmacol 33, 499-506.
36. Shively CA, Tarka SM Jr (1984) Methylxanthine composition and consumption patterns of cocoa and chocolate products. Prog Clin Biol Res 158, 149-178.
37. Nurk E, Refsum H, Drevon CA, Tell GS, Nygaard HA, Engedal K, Smith AD (2009) Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr 139, 120-127.
38. Nehlig A (2013) The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br J Clin Pharmacol 75, 716-727.
39. Rocha L, Garcia C, de Mendonca A, Gil JP, Bishop DT, Lechner MC (1999) N-acetyltransferase (NAT2) genotype and susceptibility of sporadic Alzheimer's disease. Pharmacogenetics 9, 9-15.